Patents by Inventor Alexander Mujica

Alexander Mujica has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240092789
    Abstract: The present application relates to a compound of the formula (I), to the use thereof in electronic devices, to processes for preparing the compound, and electronic devices comprising the compound.
    Type: Application
    Filed: September 16, 2020
    Publication date: March 21, 2024
    Inventors: Elvira MONTENEGRO, Teresa MUJICA-FERNAUD, Rachel TUFFIN, Frank VOGES, Amir Hossain PARHAM, Alexander Christian COMELY, Antoni MORAGAS SOLA
  • Patent number: 11910788
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: February 27, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Publication number: 20220132818
    Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.
    Type: Application
    Filed: October 20, 2021
    Publication date: May 5, 2022
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
  • Patent number: 11178860
    Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: November 23, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
  • Publication number: 20210235674
    Abstract: Non-human animals comprising a human or humanized DPP4 nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous Dpp4 gene with a human or humanized DPP4 gene, or non-human animals comprising a human or humanized DPP4 gene in addition to the endogenous Dpp4 gene are described. Non-human animals comprising a human or humanized DPP4 gene under control of human or non-human DPP4 regulatory elements is also provided, including non-human animals that have a replacement of non-human Dpp4-encoding sequence with human DPP4-encoding sequence at an endogenous non-human Dpp4 locus. Non-human animals comprising human or humanized DPP4 gene sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided. Methods for making and using the non-human animals are described.
    Type: Application
    Filed: April 21, 2021
    Publication date: August 5, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Christos Kyratsous, Alexander Mujica
  • Publication number: 20210161112
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Application
    Filed: January 29, 2021
    Publication date: June 3, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Patent number: 11013220
    Abstract: Non-human animals comprising a human or humanized DPP4 nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous Dpp4 gene with a human or humanized DPP4 gene, or non-human animals comprising a human or humanized DPP4 gene in addition to the endogenous Dpp4 gene are described. Non-human animals comprising a human or humanized DPP4 gene under control of human or non-human DPP4 regulatory elements is also provided, including non-human animals that have a replacement of non-human Dpp4-encoding sequence with human DPP4-encoding sequence at an endogenous non-human Dpp4 locus. Non-human animals comprising human or humanized DPP4 gene sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided. Methods for making and using the non-human animals are described.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: May 25, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christos Kyratsous, Alexander Mujica
  • Patent number: 10939673
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: March 9, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Publication number: 20200037587
    Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.
    Type: Application
    Filed: October 21, 2019
    Publication date: February 6, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
  • Patent number: 10524458
    Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: January 7, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
  • Patent number: 10492477
    Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: December 3, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew Murphy
  • Publication number: 20190124896
    Abstract: Non-human animals comprising a human or humanized DPP4 nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous Dpp4 gene with a human or humanized DPP4 gene, or non-human animals comprising a human or humanized DPP4 gene in addition to the endogenous Dpp4 gene are described. Non-human animals comprising a human or humanized DPP4 gene under control of human or non-human DPP4 regulatory elements is also provided, including non-human animals that have a replacement of non-human Dpp4-encoding sequence with human DPP4-encoding sequence at an endogenous non-human Dpp4 locus. Non-human animals comprising human or humanized DPP4 gene sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided. Methods for making and using the non-human animals are described.
    Type: Application
    Filed: January 3, 2019
    Publication date: May 2, 2019
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Christos Kyratsous, Alexander Mujica
  • Patent number: 10212923
    Abstract: Non-human animals comprising a human or humanized DPP4 nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous Dpp4 gene with a human or humanized DPP4 gene, or non-human animals comprising a human or humanized DPP4 gene in addition to the endogenous Dpp4 gene are described. Non-human animals comprising a human or humanized DPP4 gene under control of human or non-human DPP4 regulatory elements is also provided, including non-human animals that have a replacement of non-human Dpp4-encoding sequence with human DPP4-encoding sequence at an endogenous non-human Dpp4 locus. Non-human animals comprising human or humanized DPP4 gene sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided. Methods for making and using the non-human animals are described.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: February 26, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Christos Kyratsous, Alexander Mujica
  • Publication number: 20180332833
    Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.
    Type: Application
    Filed: July 2, 2018
    Publication date: November 22, 2018
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
  • Publication number: 20180249689
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Application
    Filed: May 17, 2018
    Publication date: September 6, 2018
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Patent number: 10015953
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: July 10, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Publication number: 20170332611
    Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.
    Type: Application
    Filed: July 26, 2017
    Publication date: November 23, 2017
    Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew Murphy
  • Patent number: 9795121
    Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: October 24, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, John McWhirter, Andrew Murphy, Lynn Macdonald
  • Publication number: 20170112107
    Abstract: Non-human animals comprising a human or humanized DPP4 nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous Dpp4 gene with a human or humanized DPP4 gene, or non-human animals comprising a human or humanized DPP4 gene in addition to the endogenous Dpp4 gene are described. Non-human animals comprising a human or humanized DPP4 gene under control of human or non-human DPP4 regulatory elements is also provided, including non-human animals that have a replacement of non-human Dpp4-encoding sequence with human DPP4-encoding sequence at an endogenous non-human Dpp4 locus. Non-human animals comprising human or humanized DPP4 gene sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided. Methods for making and using the non-human animals are described.
    Type: Application
    Filed: October 17, 2016
    Publication date: April 27, 2017
    Inventors: Christos Kyratsous, Alexander Mujica
  • Patent number: 9532555
    Abstract: Non-human animals comprising a human or humanized DPP4 nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous Dpp4 gene with a human or humanized DPP4 gene, or non-human animals comprising a human or humanized DPP4 gene in addition to the endogenous Dpp4 gene are described. Non-human animals comprising a human or humanized DPP4 gene under control of human or non-human DPP4 regulatory elements is also provided, including non-human animals that have a replacement of non-human Dpp4-encoding sequence with human DPP4-encoding sequence at an endogenous non-human Dpp4 locus. Non-human animals comprising human or humanized DPP4 gene sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided. Methods for making and using the non-human animals are described.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: January 3, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christos Kyratsous, Alexander Mujica